Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Chubb
Boehringer Ingelheim
Harvard Business School
Queensland Health
AstraZeneca
McKinsey
Citi
Chinese Patent Office
Julphar

Generated: October 19, 2017

DrugPatentWatch Database Preview

INVOKANA Drug Profile

« Back to Dashboard

What is the patent landscape for Invokana, and when can generic versions of Invokana launch?

Invokana is a drug marketed by Janssen Pharms and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and three patent family members in forty-two countries and twelve supplementary protection certificates in ten countries.

The generic ingredient in INVOKANA is canagliflozin. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin profile page.

Summary for Tradename: INVOKANA

US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list39
Clinical Trials: see list18
Patent Applications: see list77
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:INVOKANA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► SubscribeYY ► Subscribe
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► SubscribeYY ► Subscribe
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-002Mar 29, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-002Mar 29, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-002Mar 29, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► Subscribe ► Subscribe
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► SubscribeYY ► Subscribe
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for INVOKANA

Drugname Dosage Strength RLD Submissiondate
canagliflozinTablets100 mg and 300 mgInvokana3/29/2017

Non-Orange Book Patents for Tradename: INVOKANA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,482,330Substituted fused heterocyclic C-glycosides► Subscribe
8,202,984Glucopyranoside compound► Subscribe
7,820,630Substituted indole-O-glucosides► Subscribe
7,084,124Substituted indazole-O-glucosides► Subscribe
7,511,022Substituted indole-O-glucosides► Subscribe
7,935,674Indole derivatives► Subscribe
7,521,430N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter► Subscribe
7,094,764Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides► Subscribe
8,785,403Glucopyranoside compound► Subscribe
7,816,331Substituted indazole-O-glucosides► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: INVOKANA

Country Document Number Estimated Expiration
Luxembourg92426► Subscribe
European Patent Office2102224► Subscribe
Taiwan200524950► Subscribe
Mexico2009005857► Subscribe
Eurasian Patent Organization200970540► Subscribe
Taiwan200637852► Subscribe
Serbia20060322► Subscribe
Israel199032► Subscribe
South Africa200903941► Subscribe
Eurasian Patent Organization010655► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: INVOKANA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00024Denmark► SubscribePRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115
4 1-2014Slovakia► SubscribePRODUCT NAME: KANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/008 20131115
426Luxembourg► SubscribePRODUCT NAME: CANAGLIFLOZINE
2014000050Germany► SubscribePRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1 /13/884/001-008 20131115
00670Netherlands► SubscribePRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118
2014008Lithuania► SubscribePRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013 11 15 EU/1/13/884/005 - EU/1/13/884/008 20131115
2014008,C1651658Lithuania► SubscribePRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013- 11-15 EU/1/13/884/005 - EU/1/13/884/008 20131115
0140011 00102Estonia► SubscribePRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013
C0034France► SubscribePRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131115
0670Netherlands► SubscribePRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Covington
Citi
Argus Health
Cantor Fitzgerald
Deloitte
Boehringer Ingelheim
Dow
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot